MCID: CHL033
MIFTS: 29

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Malignant Schwannoma

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 72
Pediatric Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7732
NCIt 50 C8094
UMLS 72 C0279987

Summaries for Childhood Malignant Schwannoma

MalaCards based summary : Childhood Malignant Schwannoma, also known as childhood neurofibrosarcoma, is related to keratocystic odontogenic tumor and osteofibrous dysplasia. An important gene associated with Childhood Malignant Schwannoma is BIRC5 (Baculoviral IAP Repeat Containing 5), and among its related pathways/superpathways are Signaling by GPCR and Cytokine Signaling in Immune system. The drugs Mechlorethamine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are cellular and hematopoietic system

Related Diseases for Childhood Malignant Schwannoma

Diseases related to Childhood Malignant Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 keratocystic odontogenic tumor 10.0 CCND1 BIRC5
2 osteofibrous dysplasia 9.8 SPP1 NF1
3 gastrointestinal stromal tumor 9.8 NF1 CCND1
4 malignant pleural mesothelioma 9.7 SPP1 BIRC5
5 atypical teratoid rhabdoid tumor 9.7 SPP1 CCND1
6 von hippel-lindau syndrome 9.7 NF1 CCND1
7 nervous system cancer 9.5 NF1 CCND1
8 adamantinoma of long bones 9.4 SPP1 CCND1 BIRC5

Graphical network of the top 20 diseases related to Childhood Malignant Schwannoma:



Diseases related to Childhood Malignant Schwannoma

Symptoms & Phenotypes for Childhood Malignant Schwannoma

MGI Mouse Phenotypes related to Childhood Malignant Schwannoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 BIRC5 CCND1 FN1 NF1 SPP1
2 hematopoietic system MP:0005397 9.83 BIRC5 CCND1 FN1 NF1 SPP1
3 homeostasis/metabolism MP:0005376 9.8 BIRC5 CCND1 FN1 NF1 SPP1
4 immune system MP:0005387 9.77 BIRC5 CCND1 FN1 NF1 SPP1
5 craniofacial MP:0005382 9.76 CCND1 FN1 NF1 SPP1
6 mortality/aging MP:0010768 9.65 BIRC5 CCND1 FN1 NF1 SPP1
7 integument MP:0010771 9.62 CCND1 FN1 NF1 SPP1
8 neoplasm MP:0002006 9.46 CCND1 FN1 NF1 SPP1
9 normal MP:0002873 9.26 BIRC5 CCND1 FN1 NF1
10 skeleton MP:0005390 8.92 CCND1 FN1 NF1 SPP1

Drugs & Therapeutics for Childhood Malignant Schwannoma

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
9
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Liposomal doxorubicin Phase 3 31703
13 Alkylating Agents Phase 3
14 Antirheumatic Agents Phase 3
15 Antineoplastic Agents, Phytogenic Phase 3
16 Immunologic Factors Phase 3
17 Anti-Bacterial Agents Phase 3
18 Antibiotics, Antitubercular Phase 3
19 Topoisomerase Inhibitors Phase 3
20
Isophosphamide mustard Phase 3 0
21 Etoposide phosphate Phase 3
22 Antineoplastic Agents, Alkylating Phase 3
23 Tubulin Modulators Phase 3
24 Immunosuppressive Agents Phase 3
25 Anti-Infective Agents Phase 3
26 Nucleic Acid Synthesis Inhibitors Phase 3
27 Antimitotic Agents Phase 3
28 Gastrointestinal Agents Phase 3
29 Neurotransmitter Agents Phase 3
30 Anti-Allergic Agents Phase 3
31 Serotonin Antagonists Phase 3
32 Histamine H1 Antagonists Phase 3
33 Histamine Antagonists Phase 3
34 Dermatologic Agents Phase 3
35 Serotonin Agents Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Antipruritics Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Lenograstim Approved, Investigational Phase 2 135968-09-1
40 Protein Kinase Inhibitors Phase 2
41 Imatinib Mesylate Phase 2 220127-57-1 123596
42 Adjuvants, Immunologic Phase 2
43
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
44 Analgesics Phase 1
45 Anti-Inflammatory Agents Phase 1
46 Analgesics, Non-Narcotic Phase 1
47 Cyclooxygenase Inhibitors Phase 1
48 Cyclooxygenase 2 Inhibitors Phase 1
49 Peripheral Nervous System Agents Phase 1
50 Anti-Inflammatory Agents, Non-Steroidal Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
6 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
7 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Genetic Tests for Childhood Malignant Schwannoma

Anatomical Context for Childhood Malignant Schwannoma

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

41
Bone

Publications for Childhood Malignant Schwannoma

Articles related to Childhood Malignant Schwannoma:

# Title Authors PMID Year
1
Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. 38
31241238 2019
2
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. 38
30883338 2019
3
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). 38
24303016 2013

Variations for Childhood Malignant Schwannoma

Expression for Childhood Malignant Schwannoma

Search GEO for disease gene expression data for Childhood Malignant Schwannoma.

Pathways for Childhood Malignant Schwannoma

Pathways related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 SPP1 NF1 FN1 CCND1 BIRC5
2
Show member pathways
12.73 NF1 FN1 CCND1 BIRC5
3
Show member pathways
12.56 SPP1 FN1 CCND1
4
Show member pathways
12.44 SPP1 FN1 CCND1
5 12.38 FN1 CCND1 BIRC5
6 11.8 NF1 CCND1
7 11.79 CCND1 BIRC5
8
Show member pathways
11.79 SPP1 FN1
9 11.73 SPP1 CCND1
10
Show member pathways
11.72 NF1 FN1
11 11.7 FN1 CCND1
12
Show member pathways
11.67 NF1 CCND1
13 11.58 NF1 CCND1
14 11.52 FN1 CCND1
15 11.47 FN1 CCND1
16
Show member pathways
11.26 CCND1 BIRC5
17 11.17 NF1 CCND1
18 11.11 CCND1 BIRC5
19 11.03 SPP1 FN1
20 10.86 FN1 CCND1 BIRC5
21 10.85 SPP1 CCND1
22 10.72 CCND1 BIRC5
23 10.47 NF1 FN1

GO Terms for Childhood Malignant Schwannoma

Biological processes related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 osteoblast differentiation GO:0001649 9.43 SPP1 NF1
2 positive regulation of cell proliferation GO:0008284 9.43 FN1 CCND1 BIRC5
3 wound healing GO:0042060 9.4 NF1 FN1
4 response to organic substance GO:0010033 9.37 SPP1 CCND1
5 liver development GO:0001889 9.32 NF1 CCND1
6 response to steroid hormone GO:0048545 9.16 SPP1 CCND1
7 cytokine-mediated signaling pathway GO:0019221 9.13 FN1 CCND1 BIRC5
8 extracellular matrix organization GO:0030198 8.8 SPP1 NF1 FN1

Molecular functions related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 8.96 FN1 BIRC5
2 enzyme binding GO:0019899 8.8 FN1 CCND1 BIRC5

Sources for Childhood Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....